文献速递白血病

阿那格雷与伊达比星联合诱导GSDME介导的细胞焦亡作为高PDE3A急性髓系白血病的潜在疗法

Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.
PubMed 文献 · Leukemia · 2024-10-15

本研究将磷酸二酯酶3A(PDE3A)鉴定为急性髓系白血病(AML)药物重定位的潜在新靶点。PDE3A在AML细胞中较正常细胞优先过表达,且高表达与初诊AML患者较低的无事件生存期(EFS)相关。PDE3A抑制剂阿那格雷(ANA)强烈抑制高PDE3A表达AML细胞的增殖,而对低表达者影响极小。ANA与伊达比星(IDA)联合在高PDE3A表达AML细胞系中显示出最显著的协同效应,机制为caspase-3激活触发GSDME剪切启动细胞焦亡。体内联合治疗显著降低白血病负荷并延长生存时间。

要点

  • PDE3A在AML细胞中较正常细胞优先过表达,高表达与初诊AML患者较低EFS相关
  • ANA抑制高PDE3A表达AML细胞增殖,对低表达者影响极小
  • ANA与IDA联合在高PDE3A表达AML细胞系中协同最强,经caspase-3/GSDME途径诱导焦亡

核心结论

  • 联合ANA和IDA治疗是針對高PDE3A表达AML患者的一种创新且有前景的治疗策略。

研究设计与样本

  • 本研究为体外细胞系与体内白血病动物模型研究,鉴定PDE3A为AML药物重定位的潜在新靶点。

主要发现

  • PDE3A在AML细胞中较正常细胞优先过表达,高表达与初诊AML患者较低EFS相关。
  • ANA强烈抑制高PDE3A表达AML细胞增殖,对低PDE3A表达细胞影响极小。
  • ANA与IDA联合在高PDE3A表达AML细胞系中协同效应最显著,经caspase-3激活触发GSDME剪切启动细胞焦亡。
  • 高PDE3A表达白血病动物体内联合治疗较单药和溶剂对照显著降低白血病负荷并延长生存时间。

临床怎么用

  • 作者认为,联合ANA和IDA治疗是高PDE3A表达AML患者的一种创新且有前景的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an invasive hematopoietic malignancy requiring novel treatment strategies. In this study, we identified phosphodiesterase 3 A (PDE3A) as a potential new target for drug repositioning in AML. PDE3A was preferentially overexpressed in AML cells than in normal cells, and high expression of PDE3A was correlated with lower event-free survival (EFS) in de novo AML patients. The PDE3A inhibitor anagrelide (ANA) profoundly suppresses the proliferation of high PDE3A-expressing AML cells while exhibiting minimal impact on those with low PDE3A expression. Moreover, synergistic effect of ANA with other chemotherapeutic drugs in high PDE3A expression AML cells was observed. The ANA-idarubicin (IDA) combination showed the most remarkable synergistic effect among all ANA-chemotherapeutic drugs commonly used in AML cell line models. Mechanistically, the synergy between ANA and IDA inhibited the survival of PDE3Ahigh AML cell lines through pyroptosis. This mechanism was initiated by GSDME cleavage triggered by caspase-3 activation. In vivo combination treatment of leukemic animals with high PDE3A expression significantly reduced leukemia burden and prolonged survival time compared with single-drug and vehicle control treatments. Our findings suggest that combined ANA and IDA treatment is an innovative and promising therapeutic strategy for AML patients with high PDE3A expression.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yang C, Hu Y, Gao L, et al. Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia. Leukemia. 2024. PMID: 39406931. doi:10.1038/s41375-024-02437-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。